IDEAS home Printed from https://ideas.repec.org/
MyIDEAS: Log in (now much improved!) to save this article

The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004

Listed author(s):
  • Frank Lichtenberg

This study attempts to determine the extent to which new cancer drugs introduced during the last 40 years have prolonged the lives of Americans diagnosed with cancer. We use a difference-in-differences approach: we analyze the correlation across cancer sites (breast, prostate, lung, etc.) between changes in the hazard rate of people previously diagnosed with that cancer and changes in the number of drugs that have been introduced to treat that cancer, controlling for variables likely to reflect changes in diagnostic techniques: cancer stage distribution, age at diagnosis, number of people diagnosed (incidence), and use of surgery and radiation. The rate of introduction of new cancer drugs varied considerably across cancer sites and over time. Data on cancer-site-specific drug introductions are constructed using the National Cancer Institute (NCI) Thesaurus and the Drugs@FDA database. Data on all other variables were obtained from the NCI's surveillance, epidemiology, and end results 9 Registries Database, an authoritative source of information on cancer incidence and survival in the USA. We find that the effect of the lagged stock of drugs on the hazard rate of cancer patients is negative and highly significant. This signifies that cancer sites with larger increases in the lagged stock of approved drugs had larger reductions in the hazard rate, ceteris paribus. The impact of the stock of Food and Drug Administration (FDA) approvals on the hazard rate tends to increase steadily for a number of years, peak about 8-12 years after launch, and then decline. This finding is consistent with evidence about the product life cycle of cancer drugs: utilization tends to increase steadily after FDA approval, peak about 6-10 years after launch, and then decline. The cancer stage, the age at diagnosis, and incidence variables have the expected effects on the hazard rate. New cancer drugs introduced during the period 1968-1994 are estimated to have increased the life expectancy of cancer patients by almost 1 year (0.94 years). Although the health of cancer patients is less than perfect, the increase in quality-adjusted life-years is not necessarily less than the increase in life expectancy. Since the lifetime risk of being diagnosed with cancer is about 40%, the 1978-2004 increase in the lagged stock of cancer drugs is estimated to have increased the life expectancy of the entire US population by 0.38 years. This represents about 8.8% of the overall increase in US life expectancy at birth. Estimated cost per life-year gained does not exceed $6908, which is far below recent estimates of the value of a statistical life-year.

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

File URL: http://www.tandfonline.com/doi/abs/10.1080/10438590802547142
Download Restriction: Access to full text is restricted to subscribers.

As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

Article provided by Taylor & Francis Journals in its journal Economics of Innovation and New Technology.

Volume (Year): 18 (2009)
Issue (Month): 5 ()
Pages: 407-428

as
in new window

Handle: RePEc:taf:ecinnt:v:18:y:2009:i:5:p:407-428
DOI: 10.1080/10438590802547142
Contact details of provider: Web page: http://www.tandfonline.com/GEIN20

Order Information: Web: http://www.tandfonline.com/pricing/journal/GEIN20

No references listed on IDEAS
You can help add them by filling out this form.

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

When requesting a correction, please mention this item's handle: RePEc:taf:ecinnt:v:18:y:2009:i:5:p:407-428. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Michael McNulty)

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.

This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.